



Promise Under Pressure: A Pivotal Point for Personalized Medicine

Ritz-Carlton Laguna Niguel
One Ritz Carlton Drive, Dana Point, CA 92629



○ ○ ○ 19TH ANNUAL
● ● ● PERSONALIZED
● ● ● MEDICINE CONFERENCE



Contents

PART I – November 13, 2025

8:30 a.m.	Opening Remarks	2
8:45 a.m.	The Past, Present, and Future of Innovation in Personalized Medicine: A Fireside Chat with Peter Marks, M.D., Ph.D.	2
9:15 a.m.	Beyond Gene Testing: Next Generation Personalized Medicine Diagnostic Technologies in Clinical Practice (Proteomics, Metagenomics, and Digital Tools)	2
10:00 a.m.	Networking Break Sponsored by Slone Partners	2
10:30 a.m.	Evolving Clinical Practice Trends for the Implementation of Precision Oncology	2
10:45 a.m.	The Business of Personalized Medicine: Developing Viable Commercial Strategies for Personalized Medicine Companies	2
11:30 a.m.	Blood-Based Diagnostic Strategies: Business and Clinical Approaches for the Future of Precision Oncology	3
12:00 p.m.	Lunch Break and Sponsored Lunch Breakout Sessions	3
1:00 p.m.	The Future of Cancer If We Deliver on the Promise of Emerging Early Detection Technologies	3
1:45 p.m.	Biomarkers and the Rise of Personalized Medicine in the Pharmaceutical Industry: A Keynote Interview with Eli Lilly’s Anthony Sireci, M.D.	3
2:15 p.m.	Artificial Intelligence-Driven Platforms Accelerating Biomarker and Treatment Development	3
3:00 p.m.	Networking Break Sponsored by Morrison Foerster	3
3:30 p.m.	Presentation of the 20 th Annual Award for Leadership in Personalized Medicine	4
4:00 p.m.	Emerging Personalized Medicine Disciplines: Biomarker-Driven Treatment Strategies in Cardiovascular, Neurodegenerative, Kidney, and Infectious Diseases	4
4:45 p.m.	Engaging with the Global Community Is More Important Than Ever: International Efforts in Personalized Medicine and Advanced Technologies	4
5:30 p.m.	Welcome Reception on the Data Point Lawn	5

PART II – November 14, 2025

8:30 a.m.	Opening Remarks	6
8:45 a.m.	Policies and Platforms for the Data Analysis Revolution: Reflections on Harnessing Data Technologies to Advance Precision Health	6
9:15 a.m.	Artificial Intelligence for Biomarker-Driven Clinical Decision Support and Implementation of Personalized Medicine	6
10:00 a.m.	Networking Break Sponsored by Guardant Health	6
10:30 a.m.	What Is Needed to Improve the Delivery of Personalized Medicine? A Strategic Roadmap for Implementing Precision Oncology	7
11:15 a.m.	Recognizing the Clinical Utility of Personalized Medicine: Market Access Perspectives Related to Value, Coverage, and Reimbursement	7
12:00 p.m.	Closing Remarks	7
Speakers		8
Sponsors		37

PART I · Moving Personalized Medicine Forward: Advancements and Directions for the Future

November 13, 2025

7:30 a.m. Registration and Breakfast

8:30 a.m. Opening Remarks

Daryl Pritchard, Ph.D., President, Personalized Medicine Coalition

8:45 a.m. The Past, Present, and Future of Innovation in Personalized Medicine: A Fireside Chat with Peter Marks

MODERATOR | Lauren Silvis, J.D., Senior Vice President, External Affairs, Tempus AI, Inc.

KEYNOTE SPEAKER | Peter Marks, M.D., Ph.D., Senior Vice President & Head, Infectious Diseases & Molecule Discovery, Eli Lilly; Former Director of the Center for Biologics Evaluation and Research, U.S. Food & Drug Administration; Independent Pharmaceutical Consultant

9:15 a.m. Beyond Gene Testing: Next Generation Personalized Medicine Diagnostic Technologies in Clinical Practice (Proteomics, Metagenomics, and Digital Tools)

This session explores the cutting edge of personalized medicine beyond traditional gene testing, highlighting the clinical integration of next-generation diagnostic technologies. Experts will discuss the promise and practical application of proteomics, metagenomics, and digital diagnostic tools in delivering more precise, timely, and individualized care.

MODERATOR | Yuri Fesko, M.D., Senior Vice President & Chief Medical Officer, Quest Diagnostics

Esther Abels, Founder & Chief Executive Officer, SolarisRTC

Lourdes Barrera, Executive Director, Global Medical Affairs Oncology, Precision Medicine, Merck

Chris Dingman, Chief Commercial Officer, OncoHost

10:00 a.m. Networking Break

Sponsored by Slone Partners

10:30 a.m. Evolving Clinical Practice Trends for the Implementation of Precision Oncology

This session will present updated findings from the groundbreaking research study analyzing clinical practice gaps in the implementation of personalized medicine for advanced non-small cell lung cancer (aNSCLC). Building on a previously published seven-step clinical practice gap framework, which identified key barriers to optimal use of biomarker-directed therapies, this new analysis uses more recent data to assess progress over the past four years. Attendees will gain insights into evolving clinical practice trends and ongoing challenges in delivering precision oncology

PRESENTER | Susanne Munksted, Chief Precision Medicine Officer, Diaceutics

10:45 a.m. The Business of Personalized Medicine: Developing Viable Commercial Strategies for Personalized Medicine Companies

Industry innovation in diagnostic technologies and targeted treatment strategies drives progress in personalized medicine. But the path to market is fraught with obstacles. Pioneering investors and executives reflect on how to deal with challenges and uncertainty in an increasingly variable development and market environment.

MODERATOR | Kristin Ciriello Pothier, Life Sciences Sector Leader, Global & Americas Life Sciences Deal Advisory & Strategy Leader, KPMG

Namandjè Bumpus, Ph.D., Strategic Advisor, Healthcare Policies & Scientific Strategy, Avalere Health; Former U.S. FDA Principal Deputy Commissioner

Andy Moye, Ph.D., Senior Vice President & General Manager, Data, Tempus AI, Inc.

Michael J. Pellini, M.D., General Partner, Section 32

11:30 a.m. Blood-Based Diagnostic Strategies: Business and Clinical Approaches for the Future of Precision Oncology

MODERATOR | Clifton Leaf, Visiting Member, Ellison Medical Institute; former Editor-in-Chief, *FORTUNE* Magazine

KEYNOTE SPEAKERS | Helmy Eltoukhy, Ph.D., Co-Chief Executive Officer & Chairman of the Board, and AmirAli Talasaz, Ph.D., Co-Chief Executive Officer & Director, Guardant Health

12:00 p.m. Lunch Break and Sponsored Lunch Breakout Sessions

1:00 p.m. The Future of Cancer If We Deliver on the Promise of Emerging Early Detection Technologies

By detecting molecular cancer signals in blood samples of seemingly healthy patients, a new generation of early cancer detection tests promises to put more patients on the path to personalized cancer treatment, sooner, when cancer may be more effectively treated. What might this mean for the future of cancer care? Leading voices discuss.

MODERATOR | Omar Perez, Ph.D., U.S. Head of Medical Diagnostics, AstraZeneca

Tomasz Beer, M.D., Vice President & Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences

Ora K. Gordon, M.D., Clinical Director, Population Genomics Program, Providence Health

Eric Klein, M.D., Distinguished Scientist, GRAIL

Dawn Mattoon, Ph.D., Chief Executive Officer, Mercy BioAnalytics, Inc.

1:45 p.m. Biomarkers and the Rise of Personalized Medicine in the Pharmaceutical Industry: A Keynote Interview with Eli Lilly's Anthony Sireci

MODERATOR | Clifton Leaf, Visiting Member, Ellison Medical Institute; former Editor-in-Chief, *FORTUNE* Magazine

KEYNOTE SPEAKER | Anthony (Nino) Sireci, M.D., Senior Vice President, Clinical Biomarkers, Laboratories & Diagnostics, Eli Lilly

2:15 p.m. Artificial Intelligence-Driven Platforms Accelerating Biomarker and Treatment Development

Machine learning and artificial intelligence technologies can drive biomarker discovery and validation, and more readily explore divergent effects of preventive and treatment interventions across extensive data sets. What might this mean for the future of personalized medicine and what is being done to realize that future?

MODERATOR | Douglas Clark, M.D., Chief Pathologist, Life Sciences & Diagnostics Markets Group, Agilent Technologies

Ángel Alberich-Bayarri, Ph.D., Founder & Chief Executive Officer, Quibim

Laura Carter, Ph.D., Chief Scientific Officer, Character Biosciences

Yaik Ho, Ph.D., Head of Strategy, Oncology Data Science & AI, AstraZeneca

Michael Montalto, Ph.D., Vice President, Precision Medicine Global Development, Amgen

3:00 p.m. Networking Break
Sponsored by Morrison Foerster

3:30 p.m. Presentation of the 20th Annual Award for Leadership in Personalized Medicine

The Personalized Medicine Coalition will present its 20th Annual Award for Leadership in Personalized Medicine to **George Poste, D.V.M., Ph.D.** A pioneering figure in the field, Dr. Poste is recognized for his visionary leadership and lasting contributions to advancing science, technology, and policy in personalized medicine.

PRESENTER | **Mara Aspinnall**, Partner, Illumina Ventures

AWARDEE | **George Poste, D.V.M., Ph.D.**, Regents' Professor and Del E. Webb Chair in Health Innovation; Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University

4:00 p.m. Emerging Personalized Medicine Disciplines: Biomarker-Driven Treatment Strategies in Cardiovascular, Neurodegenerative, Kidney, and Infectious Diseases

As personalized medicine expands beyond oncology, emerging disciplines are rapidly integrating biomarker discovery and genetic insights into clinical care. This panel will explore how advances in understanding the genetic mechanisms of disease are shaping biomarker-driven treatment strategies across cardiovascular, neurodegenerative, kidney, and infectious diseases. Experts will highlight the opportunities and challenges of applying personalized approaches in these fast-evolving areas of personalized medicine.

MODERATOR | **Dan Roden, M.D.**, Professor of Medicine, Pharmacology, & Biomedical Informatics; Senior Vice President, Personalized Medicine, Vanderbilt University Medical Center

Doug Biehn, President & Chief Executive Officer, Octave Bioscience, Inc.

Edward Hickey, President & Chair, American Association of Kidney Patients (AAKP)

Damon Hostin, Global Lead, Market Access, Illumina

Brad Perkins, M.D., Chief Medical Officer, Karius, Inc.

4:45 p.m. Engaging with the Global Community Is More Important Than Ever: International Efforts in Personalized Medicine and Advanced Technologies

Engaging with the global community is now more vital than ever for advancing personalized medicine, especially when considering shared knowledge, coordinated policy development, and international clinical adoption strategies. With rapid innovations in advanced technologies—including cell-based and gene therapies—new models of care are emerging, such as regional clinical delivery hubs in Europe designed to streamline patient access and accelerate implementation. Speakers will discuss efforts to harmonize regulatory frameworks and other innovative approaches to ensure equitable, timely delivery of transformative therapies worldwide.

MODERATOR | **David Morrow, Ph.D.**, Scientific Lead for Advanced Therapies, European Infrastructure for Translational Medicine (EATRIS)

Gabriele Allegri, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

Brian Heath, Senior Vice President & Global Head, Commercial, Kite Pharma

Ayah Ziyada, Ph.D. Candidate, Precision Medicine Program Manager, Center for Clinical Precision Medicine and Genomics, Hamad Medical Corporation, Qatar



PRECISION MEDICINE WELCOME RECEPTION

On the Dana Point Lawn

November 13, 2025 • 5:30 p.m.

ONE RITZ CARLTON DRIVE • DANA POINT, CA 92629

PART II · Implementing Personalized Medicine in a New Era

November 14, 2025

7:30 a.m. Registration and Breakfast

8:30 a.m. Opening Remarks

Lincoln Nadauld, M.D., Ph.D., President,
Chief Executive Officer, Culmination Bio

8:45 a.m. Policies and Platforms for the Data Analysis Revolution: Reflections on Harnessing Data Technologies to Advance Precision Health

As advanced data technologies redefine personalized medicine, strategic development and sound policy are essential to realizing their full potential. In this keynote, Stacy Cline Amin, Vice President and Chief Counsel for Global Health Regulatory and Policy at Oracle, will share her perspective on how regulatory innovation, data accessibility, and cross-sector partnerships can shape the future of precision health in the era of advanced analytics and digital transformation.

INTRODUCTION | Cynthia Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

KEYNOTE SPEAKER | Stacy Cline Amin, J.D., Vice President, Chief Counsel for Global Health Regulatory & Policy, Oracle

9:15 a.m. Artificial Intelligence for Biomarker-Driven Clinical Decision Support and Implementation of Personalized Medicine

Advances in artificial intelligence and data technologies are rapidly transforming clinical capabilities to integrate complex biomarker

and clinical data into real-time decision support, improve diagnostic accuracy, and guide treatment selection. At the same time, its adoption raises critical policy considerations related to evidence standards, clinical adoption, and regulatory oversight. This session will examine both the technical innovations driving AI-enabled clinical decision making and the policy frameworks needed to ensure these tools effectively and responsibly advance personalized medicine.

MODERATOR | Okan Ekinci, M.D., Chief Medical Information Officer & Global Head of Digital Technology, Roche Information Solutions, Roche Diagnostics

Thomas Brown, M.D., Chief Medical Officer, Sygnomics

Aradhana Ghosh, M.D., Vice President, Real-World Data, Product Development, Labcorp

Apostolia Tsimberidou, M.D., Ph.D., Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Alex Vadas, Ph.D., Managing Director & Partner, L.E.K. Consulting

10:00 a.m. Networking Break
Sponsored by Guardant Health

10:30 a.m. What Is Needed to Improve the Delivery of Personalized Medicine? A Strategic Roadmap for Implementing Precision Oncology

Our scientific understanding and technological development for personalized medicine is way ahead of the policies and practices needed to fully realize the field’s value. Clinical implementation of personalized medicine technologies is fraught with challenges. A community approach to developing and implementing strategies to more consistently and effectively deliver personalized medicine is gaining traction, but there is still work ahead to realize the potential for patients. Leaders on the frontlines of delivery of care share their perspectives on what is needed to improve access and implementation.

MODERATOR | **Burns Blaxall**, Ph.D., Principal Consultant, PMG Insights

Suzette Arnal, Ph.D., Vice President, Precision Medicine, Oncology & Multispecialty

Jonathan Katchmore, Associate Vice President, Commercial Diagnostic Strategy, Eli Lilly

Rob Monroe, M.D. Ph.D., Chief Scientific Officer, Oncology, Danaher Diagnostics; Chief Medical Officer, Leica Biosystems

Prajit Pillai, Ph.D., Co-Founder, Head of Business Strategy & Technology Development, Precision Medicine Diagnostic Partners

11:15 a.m. Recognizing the Clinical Utility of Personalized Medicine: Market Access Perspectives Related to Value, Coverage, and Reimbursement

Evidence of clinical utility is central to how payers and providers assess value, set coverage policies, and determine reimbursement for personalized medicine technologies. Experts will discuss the evidentiary standards necessary for bringing personalized medicine technologies to market, and strategies to ensure patients have timely access to innovative biomarker-driven diagnostics and therapies.

MODERATOR | **Suzanne Belinson**, Ph.D., Vice President, Commercial Markets, Tempus AI, Inc.

Lon Castle, M.D., Chief Medical Officer, Precision Medicine, EviCore healthcare

Cate Lockhart, Pharm.D., Ph.D., Chief Science Officer, Academy of Managed Care Pharmacy

Kathryn Phillips, Ph.D., Founding Director, Center for Translational & Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco

12:00 p.m. Closing Remarks

J. Brian Munroe, Vice President, Government Affairs, Bausch Health Companies Inc.

12:05 p.m. Lunch Buffet

Speakers



Esther Abels

Founder & Chief Executive Officer

SolarisRTC

Esther Abels, Chief Executive Officer & founder SolarisRTC LLC, Chief Executive Officer & co-founder SolarisRTC Europe challenges the status quo to accelerate bringing innovative, emerging products to patients, globally by sharing her Regulatory, Clinical, Quality, In Vitro Diagnostics (IVD) and Pharma knowledge gained over the last 27 years.

She drives efforts for clarifying regulatory paths, reimbursement in Digital Pathology (DP) by collaborating with different Pathology Associations, Health Care Providers, Government and Payers. She successfully lead the reclassification of Whole Slide Imaging Devices in Digital Pathology from a PMA (class III) to a 510(k) (class II), and successfully lead efforts to having Digital Pathology Artificial Intelligence (AI) algorithms certified under IVD Regulations in Europe, making the company she worked for at that time being the first achieving this in digital pathology.

In 2022 she was the president for the Digital Pathology Association, and has chaired its Regulatory and Standards Taskforce and Pharma TaskForce, the AI Act working group and co-founded the Pathology Innovation Collaborative Community. At the moment she is a member of the steering committee of the DDx foundation.



Ángel Alberich-Bayarri, Ph.D.

Founder & Chief Executive Officer

Quibim

Angel Alberich-Bayarri is the Chief Executive Officer and co-founder of Quibim, a global company specializing in designing and developing pioneering tools that combine advanced medical image analysis and AI to achieve precise diagnoses and suitable treatments. Their recent solutions have focused on cancer detection and prediction. He holds a degree in Telecommunications Engineering from the Polytechnic University of Valencia and a doctorate in Biomedical Engineering. He is the inventor of 7 patents and has received numerous international awards for his innovative work, including the MIT Innovators Under 35. With 15 years of experience in the medical imaging and computer vision field, he possesses deep knowledge of the challenges and opportunities in diagnostics and drug development. He has authored over 100 articles in prestigious international journals and is a featured speaker at major international conferences.



Gabriele Allegri

Vice President, Global Commercial Precision Medicine

Johnson & Johnson Innovative Medicine

Gabriele Allegri, M.B.A., serves as Vice President, Global Commercial Precision Medicine at Johnson & Johnson Innovative Medicine. In this capacity, Allegri develops and manages global commercial strategy as well as commercial collaborations with leading diagnostics companies to help ensure that its pharmaceutical products are directed to the right patients at the right time.



Stacy Cline Amin, J.D.

Vice President, Chief Counsel for Global Health Regulatory & Policy

Oracle

Stacy Cline Amin leads the global legal, regulatory affairs, and regulatory policy teams for Oracle's Health and Life Sciences Legal & Compliance Group. She previously served as General Counsel of the Food and Drug Administration (FDA), leading an office of 170 lawyers and staff navigating complex legal, regulatory, litigation and compliance issues across the agency. She served as a Senior Associate Counsel in the White House in President Trump's first term and also in the U.S. Senate and House of Representatives. After leaving the government, she chaired the global FDA & Healthcare Regulatory & Compliance practice at Morrison Foerster, advising pharma, biotech and medtech clients on their most complex challenges and strategic priorities. She began her career as a corporate lawyer at Sullivan & Cromwell and graduated from Harvard Law School.



Suzzette Arnal, Ph.D.

Vice President, Precision Medicine, Oncology & Multispecialty

McKesson

Suzzette Arnal is a leader in molecular oncology and precision medicine with over 20 years of experience expanding access and clinical adoption of innovative diagnostics. She combines scientific expertise and business acumen with a passion for operational excellence. Suzzette has held leadership roles at Quest Diagnostics and Castle Biosciences that spanned the full lifecycle of innovation—driving product development, validation, and commercialization. She earned her undergraduate degree in Biology from Columbia University and a Ph.D. in Molecular Oncology from New York University.

As Vice President of Precision Medicine, she leads initiatives that optimize laboratory services, reimagine the delivery of hereditary cancer genetics, and accelerate the adoption of precision medicine across The US Oncology Network, advancing enterprise-wide initiatives that incorporate biomarker testing, targeted therapies, and personalized care models for more than 600 community-based oncology sites of care and 2,500 oncology providers.



Mara Aspinall

Partner

Illumina Ventures

Mara Aspinall is a healthcare leader with a commitment to civic involvement. Aspinall is a Partner at Illumina Ventures, an independent, venture capital firm focused on genomics and precision health investing in diagnostics, life science tools and therapeutics.

Aspinall was President and CEO of Ventana Medical Systems, now Roche Tissue Diagnostics, a worldwide leader in tissue-based cancer diagnostics. Previously, Mara was President of Genzyme Genetics and Genzyme Pharmaceuticals.

Aspinall is passionate about diagnostics education. She publishes Sensitive & Specific: The Testing Newsletter and the annual Diagnostics Year in Review. This commitment to expanding knowledge inspired Aspinall to co-found the Biomedical Diagnostics Master Degree program at Arizona State University, the only program dedicated exclusively to diagnostics and testing.

During the pandemic, Aspinall emerged as a national authority on COVID testing. She was co-author of The Rockefeller Foundation's reports on COVID policy.

Aspinall was Arizona Biosciences Leader of the Year by the Arizona BIO and one of "100 Most Inspiring People in Life Sciences" by PharmaVOICE magazine.



Lourdes Barrera, Ph.D.

Executive Director, Global Medical Affairs, Precision Medicine

Merck

Lourdes Barrera is Executive Director of Global Medical Affairs, Precision Medicine at Merck. She has held leadership roles at Novartis and AstraZeneca, where she built commercial and medical affairs capabilities and developed precision medicine strategies across multiple tumor types and hematological diseases.

Her early career spans over 15 years of experience as a clinical researcher in immunology, Lourdes initially focused on respiratory diseases and spent the last decade of this period specializing in lung cancer. She is also a professor of graduate and postgraduate courses, sharing her expertise with the next generation of scientists and clinicians.

Lourdes has authored more than 50 peer-reviewed publications and presented at numerous international congresses. She holds a Bachelor's degree in Biology, Chemistry, and Pharmacy (honors), as well as dual doctorates in Immunology and Science Communication from the National Autonomous University of Mexico.



Tomasz (Tom) Beer, M.D.

Vice President & Chief Medical Officer, Multi-Cancer Early Detection

Exact Sciences Corporation

Dr. Tomasz (Tom) Beer serves as Vice President & Chief Medical Officer for Multi-Cancer Early Detection (MCED) at Exact Sciences Corporation. He oversees the clinical development of the company's MCED test, to expand screening beyond the handful of cancers screened for today.

Prior to Exact Sciences, Dr. Beer was Chief Medical Officer and Deputy Cancer Center Director for the Center for Early Detection Advanced Research (CEDAR) where he led collaborations among clinicians, engineers, and cancer biologists and directed clinical trials of multi-omic blood-based cancer early detection tests.

Dr. Beer has authored or co-authored more than 290 peer reviewed articles on multi-cancer early detection, cancer survivorship, and emerging therapies. His work definitively showed overall survival gains with enzalutamide therapy, establishing a new standard of care for advanced prostate cancer.

Dr. Beer also maintains an adjunct faculty appointment at the Oregon Health & Science University (OHSU) Knight Cancer Institute, where he sees men with prostate cancer and serves on the American Cancer Society's Discovery Council.



Suzanne Belinson, Ph.D.

Vice President, Commercial Markets

Tempus AI, Inc.

Suzanne Belinson, Ph.D., MPH, is Vice President of Commercial Markets at Tempus AI, Inc. Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI, in healthcare to create Intelligent Diagnostics. Dr. Belinson's role is focused on commercial growth through the development and execution of partnerships with managed care organizations. She is focused on improving healthcare value and outcomes by leveraging molecular and clinical data.

Previously, Dr. Belinson served as Executive Director, Clinical Markets, at the Blue Cross Blue Shield Association where she led the sales and market development as well as day to day operations of Evidence Street.

Dr. Belinson received her bachelor's degree from Cleveland State University, a Masters in Public Health from the University of Pittsburgh, and a Ph.D. in Epidemiology from the University of North Carolina at Chapel Hill.



Cynthia Bens

Senior Vice President, Public Policy

Personalized Medicine Coalition

Cynthia A. Bens serves as the Senior Vice President for Public Policy at the Personalized Medicine Coalition (PMC). In this capacity, she leads the Coalition's policy development and government relations efforts and serves as its primary liaison with the U.S. Congress and federal regulators. Bens is responsible for implementing research, regulatory, and reimbursement policy strategies that promote the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and health systems.



Doug Biehn

President & Chief Executive Officer

Octave Bioscience

Doug Biehn is an accomplished leader with over 20 years of healthcare experience building and scaling growth businesses, leading and inspiring world class teams and establishing innovative new standards of care.

Prior to joining Octave, Doug held executive leadership roles in such category creating and industry leading companies as iRhythm Technologies, McKesson, AliveCor, Blue Shield of California and most recently, Cala Health. Additionally, he is a Board Advisor for a number of early-stage digital health companies and mentors graduate students in the Stanford Business School Lean Launchpad program. Doug holds an MBA from the University of San Francisco and a BS from San Francisco State University.



Burns Blaxall, Ph.D.

Principal Consultant

PMG Insights

Dynamic healthcare and academic leader with over 25 years of experience driving innovation in precision and preventive medicine, implementation science, translational and clinical research, and health system transformation. Passionate about shifting healthcare from reactive to proactive as well as health equity and wellness. Recognized for a strong track record of implementing precision medicine into clinical workflow with decision support, risk assessment tools to improve outcomes, and value-based care. Skilled in forging strategic partnerships across healthcare, academia, and industry. Led multi-million-dollar initiatives, established and scaled research centers, clinics, and precision health programs. Successfully secured tens of millions in competitive funding, with impactful publications and invited lectures across six continents aiming to advance personalized, proactive care.



Thomas Brown, M.D.

Chief Medical Officer

Sygnomics

Dr. Thomas Brown is an internationally renowned oncologist and cancer researcher, and the Chief Medical Officer of Sygnomics. He previously worked with the Swedish Cancer Institute (SCI) at Providence St. Joseph Health (PSJH), where he served as Executive Director of SCI, and led the establishment of the SCI Personalized Medicine Program. Dr. Brown also served in leadership roles across PSJH, including co-chair of the PSJH Cancer Leadership Council and co-chair of the PSJH Genomics Initiative.

Dr. Brown's clinical and research efforts have been focused on gastrointestinal (GI) malignancies, broad developmental therapeutics in oncology, specifically phase I and II clinical trials, and health care policy and global medicine. He has been a leader in large-scale clinical trials and research programs for some of the most innovative academic medical centers and research collaborations and has spent the past decade pioneering approaches to real-world evidence in a health system setting.



Namandjé N. Bumpus, Ph.D.

Strategic Advisor, Healthcare Policies & Scientific Strategy

Avalere Health

Former U.S. FDA Principal Deputy Commissioner

Dr. Namandjé N. Bumpus serves as a strategic advisor in regulatory science and policy, formerly serving as the FDA's Principal Deputy Commissioner until December 31, 2024. She began at the FDA in August 2022 as Chief Scientist before advancing to the agency's no. 2 role, overseeing operations and public health initiatives. Prior to the FDA, Dr. Bumpus was the E.K. Marshall and Thomas H. Maren Professor and Director of Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine, following a postdoctoral fellowship at The Scripps Research Institute. She holds a PhD in pharmacology from the University of Michigan and a bachelor's in biology from Occidental College. Dr. Bumpus is a past-president of the American Society for Pharmacology and Experimental Therapeutics, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine.



Laura Carter, Ph.D.

Chief Scientific Officer

Character Biosciences

Laura Carter, Ph.D. is the Chief Scientific Officer at Character Biosciences, a precision medicine company that is unlocking the patterns of progressive polygenic diseases in ophthalmology, starting with dry AMD. Following her PhD and postdoctoral studies in Molecular Pathology and Immunology, Dr. Carter has over 20 years of experience in the biotech/pharmaceutical industry where she has led R&D activities in multiple disease areas and contributed to the discovery and development of several approved drugs. Prior to joining Character Biosciences, Dr. Carter was the Chief Scientific Officer at Gossamer Bio where she was responsible for research, non-clinical development and translational biology across a diverse portfolio. Previously, Dr. Carter was Senior Vice President, Biology at Lycera Corporation, Scientific Director in the Respiratory, Inflammation and Autoimmunity group at MedImmune, and a Senior Research Investigator in the Inflammation Biology and Translational Science department at Array Biopharma. She started her industry career at Wyeth where her studies identified new cytokines and the negative regulatory role of PD-1:PD-L interactions on T cell function.



Lon Castle, M.D.

Chief Medical Officer, Precision Medicine

EviCore healthcare

Dr. Castle has been responsible for the clinical development and performance of the Laboratory, Specialty Drug and Gene Therapy programs at EviCore by Evernorth for over 9 years. In addition to his 15 years of experience in the Specialty Drug field, Dr. Castle has been working in the genomic and molecular diagnostic field since 2007. During this time, he has been responsible for both designing initiatives that support the advancement of precision medicine and developing programs that ensure these tests are used appropriately.

Dr. Castle is board certified in Family Medicine. He completed his Sports Medicine fellowship at The Ohio State University in Columbus and practiced sports medicine for over a decade at the Baylor College of Medicine and the Baylor Sports Medicine Institute in Houston, Texas, serving as team physician for numerous professional, college, and high school sports teams.

Dr. Castle, much to his eternal dismay, is an avid Cleveland sports fan. Nothing more needs to be said, other than this undoubtedly contributed to his enjoyment of, and interest in, wine.



Douglas Clark, M.D.

Chief Pathologist, Life Sciences & Diagnostics Markets Group

Agilent Technologies

Dr. Douglas P. Clark is a physician-scientist, pathologist, and health care executive whose career has spanned academic medicine, biomedical research, entrepreneurship, and health system executive leadership. Doug is an expert in the fields of pathology artificial intelligence, cytopathology, and molecular diagnostics, and has authored over 80 peer-reviewed publications, several books and book chapters, is an inventor on several patents, and has given dozens of invited lectures nationally and internationally.

Dr. Clark currently serves as the Chief Pathologist for the Life Sciences & Diagnostics Markets Group at Agilent Technologies, a \$6.51B company with customers in 110 countries. As Chief Pathologist, Doug is responsible for defining the vision and executing the Anatomic and Molecular Pathology strategy in this rapidly evolving field. Doug extensive expertise will play a critical role in implementing Agilent's mission to improve the human condition by advancing precision medicine.



Chris Dingman

Chief Commercial Officer

OncoHost

Chris Dingman has over 24 years of experience in the healthcare industry. A top-performing, proven sales leader with extensive expertise in oncology molecular diagnostics and the pharmaceutical industries, Chris has a successful track record of developing and launching laboratory-developed tests by growing commercial and marketing capabilities. He has helped build top-tier, successful sales teams with a culture of putting patients and physicians first. Chris holds a BA in Marketing (cum laude) from the University of Colorado, Boulder, and an MBA in global management.



Okan Ekinci, M.D.

Chief Medical Information Officer & Global Head of Digital Technology,
Roche Information Solutions

Roche Diagnostics

Okan Ekinci, M.D., M.B.A., is the Head of Digital Technology and Chief Medical Information Officer at Roche Information Solutions. He joined Roche in 2018 and served as Chief Medical Officer and Senior Vice President of Marketing & Innovation for the digital health business. Before that, Okan held various positions at Siemens Healthineers, including Chief Medical Officer and Head of Healthcare Consulting. He has been a strategic advisor to healthcare institutions and governments on digital transformation and artificial intelligence. Okan is a cardiologist by training and an adjunct professor of medicine at the University College Dublin.



Helmy Eltoukhy, Ph.D.

Co-Chief Executive Officer & Chairman of the Board

Guardant Health

Helmy Eltoukhy is the chairman and co-Chief Executive Officer of Guardant Health, a leading precision oncology company he co-founded in 2012. He is also an active investor and is involved in over 30 startup companies across the technology and healthcare sectors. Last year, Eltoukhy expanded his ventures into sports ownership by co-leading the acquisition of Sheffield United Football Club through COH Sports of which he is currently co-chairman.

This year, he was named by TIME100 Health as one of the most influential people in global health. He was also on Time Magazine's inaugural list of the 50 Most Influential People in Health Care and has been recognized by Fortune (40 under 40), the World Economic Forum (Technology Pioneer), and on the list of the Top 50 Healthcare CEOs in 2021.

Beyond his entrepreneurial endeavors, Eltoukhy is deeply committed to various philanthropic efforts and serves on the boards of the Prostate Cancer Foundation, the SETI Institute (Search for Extraterrestrial Intelligence), and the UCSF Cancer Leadership Council. Prior to founding Guardant Health, Eltoukhy co-founded Avantome in 2007 to commercialize semiconductor sequencing, which was later acquired by Illumina. Eltoukhy is a named inventor on over 100 patents and holds PhD, MS, and BS degrees in electrical engineering from Stanford University.



Yuri Fesko, M.D.

Senior Vice President & Chief Medical Officer

Quest Diagnostics

As Chief Medical Officer, Dr. Fesko oversees medical affairs, including clinical development and health plan policy support for new services and care delivery models. He also leads scientific communications for the company's medical team.

Board certified in oncology, hematology and internal medicine, Dr. Fesko led clinical development of innovations such as the 500-gene somatic tumor sequencing panel and decentralized clinical trials model. He also pioneered the company's precision pathways model, helping oncologists and pathologists speed guideline-based biomarker testing for advanced cancers. In addition, he led clinical research on minimal residual disease (MRD) test technology from Haystack Oncology, informing Quest's 2023 acquisition to establish leadership in cancer recurrence testing.

Prior to Quest, Dr. Fesko was medical director of oncology at Duke Cancer Center in Raleigh, N.C., and chief of oncology for Wake County, N.C. He completed his fellowship in hematology and oncology and earned his medical and bachelor's degrees from Case Western Reserve University. He has authored multiple peer-reviewed publications.



Aradhana Ghosh, M.D.

Vice President, Real-World Data Product Development

Labcorp

Aradhana Ghosh, M.D. is a board-certified Medical Oncologist and seasoned Clinical Informaticist who currently serves as Vice President of Real-World Data Product Development at Labcorp. In this role, she leads a multi-disciplinary team of clinicians, scientists, and technologists who work cross-functionally as domain experts to build and implement data-centric products. For more than 10 years, Aradhana has been working at the intersection of clinical data and innovative technology to enable precision medicine and achieve better health outcomes.

Dr. Ghosh joined Labcorp in 2022, and prior to that, she held other positions including at Genentech/Roche, McKesson, and Kaiser Permanente where she began her clinical career. Aradhana earned her medical degree at Albany Medical College and completed residency and fellowship at Temple University Hospital and New York-Presbyterian/Weill Cornell Medical Center, respectively.



Ora K. Gordon, M.D.

Clinical Director, Population Genomics Program

Providence Health

Dr. Gordon is the Clinical Director of Providence Health's Population Genomics Program. In this role, Dr. Gordon leads system-wide clinical and research protocols for population genomic medicine across the Providence 50 hospital integrated network and is the principal investigator for the Geno4Me: Genomic Medicine for Everyone study and implementation studies of novel cell free DNA multi-cancer early detection blood tests for high-risk patients. Thousands of patients have been enrolled in these prevention and early detection studies. Locally, she is Regional Medical Director of the Clinical Genetics & Genomics Program, Providence Southern California overseeing services throughout Los Angeles and Orange Counties.

Dr. Gordon is a professor of genetics at Saint John's Cancer Institute (formerly John Wayne Cancer Institute) and professor of medicine at UCLA Geffen School of Medicine. She graduated from Tulane University and earned her Master of Science and medical degrees from the University of California, Irvine. She completed her internship and residency at the University of California, Los Angeles, where she also completed a fellowship in genetics and is board certified in internal medicine and medical genetics. In addition to her research publications, she also has co-authored an award-winning book for women facing genetic risk for breast or ovarian cancer, called *Positive Results: Making the Best Decisions When at High Risk for Breast and Ovarian Cancer*.



Brian Heath

Senior Vice President & Global Head, Commercial

Kite Pharma

Brian Heath joined Kite in 2025 as Senior Vice President and Head of Global Commercial.

Brian is a highly accomplished leader with over 25 years of experience building and leading commercial teams across diverse geographies and therapeutic areas, with a strong focus in hematology and oncology. Prior to joining Kite, he served as Vice President and General Manager of Amgen's US Oncology Business Unit, responsible for the commercialization of fifteen innovative and biosimilar medicines. His global experience includes leadership roles across Latin America, Turkey, the Middle East, Africa, and Canada, where he served as Vice-Chair of the Board of Innovative Medicines Canada.

He holds a bachelor's degree from Brigham Young University and an MBA from the Harvard Business School. Brian is committed to community service, serving on the Board of Directors for Food Share of Ventura County.



Edward Hickey

President & Chair

American Association of Kidney Patients (AAKP)

Mr. Hickey is an attorney with O'Melveny & Myers, an international, 800-lawyer firm with 15 offices worldwide. He is a member of the Litigation Department and Director of the firm's eDiscovery staff attorneys, leading operations firmwide. He served as an Infantry officer in the U.S.M.C. as a Lieutenant with postings in Quantico and Camp Pendleton.

His public service career includes roles on Capitol Hill, at the United States Department of Commerce and, after September 11, 2001, as Senior Advisor for Homeland Security for the Director of the Office of Personnel Management under President George W. Bush. At OPM, Mr. Hickey served as liaison to Veteran Service Organizations and coordinated with Congress and the White House on veterans' legal rights during civil service reforms. He is a recipient of a Silver Helmet Award from AMVETS.

Mr. Hickey supports veterans through the Inner City Law Center of Los Angeles. He is also active in the Armed Forces Committee and Veterans Legal Service Project of the Los Angeles County Bar Association, assisting veterans, military personnel, and reservists with legal needs.



Yaik Ho, Ph.D.

Head of Strategy, Oncology Data Science & AI

AstraZeneca

Yaik Ho has a robust background in oncology and competitive analysis, with experience as Head of Competitor Analysis for the Oncology Business Unit at AstraZeneca from September 2015 to July 2017, where leadership in competitive analysis was pivotal. Prior to this role, Yaik Ho served as Director of Oncology, managing strategy and operations within the oncology division. At Prescient Healthcare Group from May 2012 to August 2015, planning and executing competitive tracking programs for pharmaceutical clients were key responsibilities, with a focus on oncology and related fields. Additionally, Yaik Ho worked as a Research Associate at Imperial College London from November 2011 to April 2012, contributing to scientific research in a collaborative setting. Educational qualifications include a Doctor of Philosophy (PhD) and a Master of Science (MSc) from the University of Leicester.



Damon Hostin

Global Lead, Market Access

Illumina

Damon Hostin Leads the Global Market Access at Illumina. Previously, he led the Precision Medicine Alliance of Catholic Health Initiatives and Dignity Health/ CommonSpirit Health, bringing advanced diagnostic and data solutions to over 150 hospitals. Prior, he was clinical lead for Complete Genomics, driving genomic analysis for rare disease. Earlier, he was General Manager of the Life Science segment of Strategic Diagnostics' antibody and assay business, including IVDs, research tools and therapeutic mAb generation. Earlier, Hostin was Head of Life Science GenVis Labs, a genetic Dx company purchased by Pfizer in 2005. As a founding member of Actinium Pharmaceuticals, he managed alliances in developing targeted oncology radiotherapeutics. As Team Leader, Sequencing at Celera Genomics, he was published on the Human and Drosophila genomes in Science and contributed to pharmaceutical partnerships. His education includes undergraduate studies at Tulane University, Master's studies at Harvard University, and certificate programs at TIGR, the NIH, and Wharton.



Jonathan Katchmore

Associate Vice President, Commercial Diagnostic Strategy

Eli Lilly

Jonathan Katchmore has over 20 years of experience in the diagnostic/BioPharma industry. He currently serves as the Associate Vice President of Commercial Diagnostic Strategy at Lilly where he leads strategy and execution of all external commercial initiatives in the precision medicine space. His focus is on working with external partners to develop innovation solutions that address the clinical practice gaps that inhibit patients from benefiting from a personalized medicine approach. Prior to joining Lilly, Jonathan spent 6 years at Foundation Medicine where he launched Next Generation Sequencing into the market.



Eric A. Klein, M.D.

Distinguished Scientist

GRAIL

Eric A. Klein, M.D. is Distinguished Scientist at GRAIL. Previously he served as the Andrew C. Novick Distinguished Professor and Chair of the Glickman Urological and Kidney Institute and Lerner College of Medicine of the Cleveland Clinic, where he was also a member of the Department of Cancer Biology of the Cleveland Clinic Lerner Research Institute, the Taussig Cancer Institute, and the Genitourinary Malignancies Program in the Case Comprehensive Cancer Center. Dr. Klein was a Fellow in the Distinguished Careers Institute at Stanford University in 2022 and joined GRAIL in 2023. His recent work has focused on the clinical development of multi-cancer early detection tests.



Clifton Leaf

Visiting Member

Ellison Medical Institute

Former Editor-in-Chief

FORTUNE Magazine

Clifton Leaf, an adjunct professor of journalism at Columbia University's Graduate School of Journalism, served as the editor-in-chief of Fortune from 2017 to 2021. During his tenure, *Fortune* won more than 70 top journalism prizes, substantially expanded its website, newsletter, premium subscription, podcast, and virtual conference businesses, and launched two new start-up businesses in career development and education, respectively. Prior to that he was *Fortune*'s deputy editor, overseeing the acclaimed print magazine. In earlier years, he was a guest editor for the *New York Times* op-ed page and held senior positions at the *Wall Street Journal*'s *SmartMoney* magazine and at *Fortune*.



Cate Lockhart, Pharm.D., Ph.D.

Chief Science Officer

Academy of Managed Care Pharmacy (AMCP)

Cate Lockhart, Pharm.D., Ph.D. is the Chief Science Officer of the Academy of Managed Care Pharmacy (AMCP) and the Executive Director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) where she is responsible for all AMCP research programs, including those within the BBCIC multi-stakeholder research collaboration. She is a proven leader in health economics and outcomes research (HEOR), observational research, and managed care pharmacy through experience in the biopharmaceutical sector, experience as a consultant, and her current role at the AMCP. Cate has three undergraduate degrees: Electrical Engineering, Visual Communications, and Theatre Arts. She also has three advanced degrees: Pharm.D., M.S. in HEOR, and a Ph.D. in Pharmaceutical Sciences. She has one U.S. Patent.



Peter Marks, M.D., Ph.D.

Senior Vice President & Head, Infectious Diseases & Molecule Discovery

Eli Lilly

Former Director of the Center for Biologics Evaluation and Research

U.S. Food & Drug Administration

Independent Pharmaceutical Consultant

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women's Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. In 2012, he joined the Food and Drug Administration and served as Director of the Center for Biologics Evaluation and Research from 2016 to 2025. During that time, he was integrally involved in the response to several public health emergencies and was elected to the National Academy of Medicine in 2022. He has published extensively and is a member of multiple professional societies. He is currently working as an independent consultant.



Dawn Mattoon, Ph.D.

Chief Executive Officer

Mercy BioAnalytics Inc.

Dr. Dawn Mattoon is the Chief Executive Officer at Mercy BioAnalytics. She brings nearly 20 years of experience in the biotechnology industry and has held leadership positions in R&D, Strategy, and General Management for a series of exceptional companies including Invitrogen, Life Technologies, Thermo Fisher, and Cell Signaling Technology. Prior to joining Mercy, Dr. Mattoon served as the Senior Vice President for Clinical Diagnostics at Quanterix, where she led the development and commercialization of the company's first two FDA authorized diagnostic tests for COVID-19, and received Breakthrough Device designations from the FDA for diagnostic tests in Alzheimer's Disease and Multiple Sclerosis. She has developed and commercialized products across a range of proteomic and genomic technologies and is thrilled by the opportunity to bring the highly innovative Mercy Halo diagnostic test portfolio to patients. Dr. Mattoon earned her Ph.D. in Genetics with a focus in signal transduction from Yale University, where she also completed her postdoctoral fellowship.



Rob Monroe, M.D., Ph.D.

Chief Science Officer, Oncology

Danaher Diagnostics

Chief Medical Officer

Leica Biosystems

Dr. Rob Monroe is a physician scientist currently serving as Chief Medical Officer for Leica Biosystems and Chief Scientific Officer, Oncology for Danaher Diagnostics. Prior to Danaher, Dr. Monroe served as Chief Medical Officer of Bio-Techne; Chief Medical Officer at Advanced Cell Diagnostics; VP of Laboratory Operations at Veracyte; and Chief Medical Officer at Bioluminate, one of the pioneering digital pathology companies. During his industry career, Rob also co-founded OncoMDx, a molecular diagnostics laboratory that later became part of Core Diagnostics where he served as Chief Medical Officer and led an international digital pathology service. Before joining industry, Rob practiced pathology in the Central Coast of California following a Medical Scientist Training Program Scholarship at Harvard Medical School and residency training at UCLA and Stanford.



Michael Montalto, Ph.D.

Vice President, Precision Medicine, Global Development

Amgen

Dr. Montalto is an industry leader in translational and precision medicine, digital pathology and AI for biomarker discovery.

Prior to Amgen, Dr. Montalto was the Chief Scientific Officer of PathAI, and Vice President of Translational Sciences at Bristol Myers Squibb. He has led teams to invent, develop and launch digital pathology, spatial multiplexing and AI-powered software applications as well as flagship biomarker testing programs such as PharmDx 28-8 (PD-L1/Agilent) for Opdivo, Yervoy and Opdualag.

Dr. Montalto serves on the Executive Committee of FNHI Biomarker Consortium, the editorial board of the Journal of AI in Precision Oncology and is a member of the Friends of Cancer Research Digital Pathology Working Group. He is the former President and board member of the Digital Pathology Association, has served as a scientific advisor to various multinational and start-up companies, holds 10 U.S. patents and has authored over 100 publications. Dr. Montalto earned his Ph.D. in tumor biology from Albany Medical College and completed post-doctoral training at Brigham and Women's Hospital and Harvard Medical School.



David Morrow, Ph.D.

Scientific Lead, Advanced Therapies

European Infrastructure for Translational Medicine (EATRIS)

David Morrow is the Scientific Lead for Advanced Therapies at EATRIS, where he drives the scientific strategy for Advanced Therapy Medicinal Products (ATMP) and Vaccines, Inflammation and Immune Monitoring (VIIM). He plays a central role in building European networks of scientific and clinical expertise to address shared challenges in translating ATMPs to the clinic and contributes to multiple EU-funded collaborative projects. David earned a BSc in Molecular Biology from University College Dublin (2001) and a PhD in Vascular Biology from Dublin City University (2006), followed by an American Heart Association Fellowship at the University of Rochester, NY, where he received the AHA Young Investigator Award (2008). From 2009–2015, he was a Principal Investigator funded by the NIH and AHA, leading translational projects in cardiovascular disease and oncology. He also holds an MBA in Health Science Management and has worked in consulting and technology transfer. David serves on several Scientific Advisory Boards and international initiatives in the ATMP field.



Andy Moye, Ph.D.

Senior Vice President & General Manager, Data

Tempus AI, Inc.

Andy Moye is currently the Senior Vice-President and General Manager of Real-world Data for Tempus AI, a company dedicated to improving patient outcomes through AI and data. He was previously Chief Executive Officer and board member for Paige, a spin-out company from Memorial Sloan Kettering Cancer Center in New York City. Andy has always been driven to serve others, and began his career as a Flight Officer in the US Navy, flying missions in Iraq and the Middle East from 1998 through 2006. Dr. Moye is also passionate about making a difference in the fight against cancer, and has worked across the molecular diagnostics, biotechnology, Real World Data (RWD), and life sciences industries at the forefront of precision medicine in oncology. Notably, he served as Head of Commercial Operations in North America and Latin America for Philips Digital Pathology solutions, and in senior executive roles at leading healthcare companies including Ontada, a division of McKesson, Caris Life Sciences, and WaferGen Bio-systems, now part of Takara Bio. Andy Moye's educational career includes a Bachelor of Science in Physiology from the University of Arizona, an M.B.A. from the University of Florida, and a Ph.D. in Health Economics from Walden University.



Susanne Munksted

Chief Precision Medicine Officer

Diaceutics

Susanne brings a wealth of experience to her role in leading a global team of precision medicine industry experts dedicated to enhancing the testing ecosystem to help patients capitalize on new breakthrough personalized medications. Susanne's journey in molecular pathology has been marked by notable achievements, including spearheading several global launches of companion diagnostic products. As a leading author of the Practice Gaps Study, Susanne played a pivotal role in identifying 7 key clinical Practice Gaps contributing to patient leakage, and her impactful contributions to the field have earned her a well-deserved place among the PharmaVoice 100 list of transformational leaders in life sciences.



J. Brian Munroe

Vice President, Government Affairs

Bausch Health Companies Inc.

A 25-year veteran of health care public policy, advocacy, and communications, Brian's areas of expertise include FDA legislation and regulations, Medicare and Medicaid reimbursement, federal and state tax policy, and the development of government policies to advance personalized medicine. Brian has created successful, stand-alone Government Affairs Departments from scratch at: SmithKline Beecham, Millennium Pharmaceuticals, and Endo Pharmaceuticals. He is currently Vice President, Government Affairs, at Bausch Health Companies.



Lincoln Nadauld, M.D., Ph.D.

President, Chief Executive Officer

Culmination Bio

Lincoln Nadauld, M.D., Ph.D., is the CEO of Culmination Bio, a clinical insights company spun out of Intermountain Healthcare. Dr. Nadauld previously served as the Chief of Precision Health at Intermountain Healthcare, where he founded the Intermountain Precision Genomics program with a vision of finding solutions to improve health and disease through genomics and precision medicine without increasing costs. With this vision in mind, he oversaw the clinical implementation of precision genomics across Intermountain's 24 hospitals and 160 physician clinics.



Michael J. Pellini, M.D.

General Partner

S32

Mike is a General Partner of S32, a venture capital firm investing at the frontiers of technology.

Prior to joining S32 in 2017, he served as Chief Executive Officer of Foundation Medicine, which transformed how pharma and physicians evaluate genomic changes in cancer, later serving as Chairman through Roche's (RHHBY) acquisition in 2018. Previously, he was President and Chief Operating Officer of Clariant, a national leader in molecular pathology, acquired by GE Healthcare in 2010.

He currently serves on the Board of Directors for Nusano, Octave BioSciences, TwinStrand Genomics, Exai Bio, and Delve Bio. He has also served on the boards of the American Cancer Society, Thrive Earlier Detection—acquired by Exact Sciences (EXACT) in 2021, Tango Therapeutics (TNGX), Adaptive Biotechnologies (ADPT), and Singular Genomics (OMIC). Mike brings deep expertise in personalized medicine, with a passion for defeating cancer.

During the COVID pandemic, Mike served as a Senior Advisor to the Rockefeller Foundation's efforts on COVID-19 testing.

Mike received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.



George Poste, D.V.M., Ph.D.

Regents' Professor and Del E. Webb Chair in Health Innovation;
Chief Scientist, Complex Adaptive Systems Initiative

Arizona State University

Dr. George Poste is the Del E. Webb Professor of Health Innovation and Chief Scientist at Arizona State University's Complex Adaptive Systems Initiative (CASI), which integrates genomics, synthetic biology, and high-performance computing to develop diagnostic technologies and remote health monitoring tools for precision medicine. He also leads the Institute for Future Health, a joint venture between ASU and the University of Arizona advancing digital and precision health.

From 2003 to 2009, Dr. Poste served as Founding Director of ASU's Bidesign Institute. Earlier, he was Chief Science and Technology Officer and President of R&D at SmithKline Beecham (now GlaxoSmithKline), where he helped guide the development and approval of numerous drugs, vaccines, and diagnostic products.

Dr. Poste has published over 400 scientific papers, edited 14 books, and holds multiple honorary degrees. He has received major recognitions including the Commander of the British Empire, the Einstein Award, and the Scrip Lifetime Achievement Award.

He serves on the boards of Exelixis, Caris Life Sciences, and MediSix, and on the advisory boards of several research institutes and biotechnology companies. He is a Fellow of the Royal Society, the Royal College of Pathologists, the U.K. Academy of Medicine, and the American Institute for Medical and Biological Engineering.

Dr. Poste also advises U.S. defense, intelligence, and health agencies on biosecurity, emerging infectious diseases, and global biosurveillance.



Omar Perez, Ph.D.

U.S. Head of Medical Diagnostics

AstraZeneca

Dr. Omar Perez has over 17 years designing, deploying, and leading high-visibility oncology initiatives supporting global companion diagnostic developments, strategic partnerships and commercialization opportunities. Before joining AstraZeneca, he oversaw the global CDx developments for the GSK oncology portfolio, leading to diagnostic products for niraparib and dostarlimab. During his time at Pfizer, he led global CDx activities supporting the drug approvals of crizotinib, lorlatinib, dacomitinib, talazoparib and inotuzomab. Notably, he led the first FDA approved NGS product for multiple targeted agents and helped establish the Center for Precision Medicine in LATAM to support Pfizer oncology products. Dr. Perez's background includes roles in biotech and diagnostic companies, including co-founding Nodality, a diagnostic company focused on hematological malignancies. He is an inventor of the multiparametric phospho-proteomic flow technologies and an author of 37 publications and 35 patents.



Brad Perkins, M.D.

Chief Medical Officer

Karius, Inc.

Brad Perkins is the Chief Medical Officer at Karius, Inc., a global pioneer in clinical use of microbial cell-free DNA. He was founding Chief Medical Officer for Human Longevity, Inc. (HLI) where he designed the Health Nucleus, a leading precision medicine platform with genomics pioneer JC Venter. Brad was EVP for Strategy and Innovation and Chief Transformation Officer at Vanguard Health Systems, an integrated health system in the run-up to its IPO, and subsequent sale to another publicly-traded healthcare company. Brad started his career at the Centers for Disease Control and Prevention (CDC) where he led high profile investigations and research globally; he led the 2001 US anthrax bioterrorism investigations following 9/11. He served as the Chief Strategy and Innovation Officer at CDC. Brad has an MD and MBA, and is Board-certified in Internal Medicine. He lives and works in San Diego and Redwood City, CA.



Kathryn Phillips, Ph.D.

Founding Director, Center for Translational & Policy Research on Personalized Medicine (TRANSPERS)

University of California-San Francisco (UCSF)

Kathryn founded the UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS) in 2008, a global leader in developing objective evidence on effectively, efficiently, and ethically implementing precision medicine. She has published over 200 articles in major journals (e.g., JAMA, NEJM, Science, Health Affairs); has led NIH grants for over 30 years; serves as the Founding Editor-in-Chief for Health Affairs Scholar; is a member of NAM committees (e.g., Roundtable on Genomics; Committee on Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden); and has served/is serving on an evidence review committee for the Institute for Clinical and Economic Review (ICER), GenomeCanada's governing Board of Directors, and as an advisor to the FDA, CDC, AHRQ, President's Council of Advisors on Science and Technology, and White House Office of Science and Technology Policy as well as many tech/pharma companies and venture capitalists. For several years, she has been among the top 2% of authors for career-long citations in her field (Ioannidis, 2024).



Prajit Pillai, Ph.D.

Co-Founder, Head of Business Strategy & Technology Development

Precision Medicine Diagnostic Partners

Prajit Pillai, Ph.D., is an accomplished scientist with extensive experience leading complex biotech and pharma projects from R&D through commercialization. He is the Co-Founder and Head of Business Strategy & Technology Development at Precision Medicine Diagnostic Partners, where he is developing AI-driven solutions to close cancer care gaps through custom clinical decision support tools. In addition, he serves as Director of Clinical Sciences at Cancer Commons, advancing their mission to leverage the latest research to improve patient outcomes. Passionate about harnessing technology to transform healthcare, Dr. Pillai actively partners with innovators to accelerate progress in cancer care.



Kristin Ciriello Pothier

Life Sciences Sector Leader, Global & Americas
Life Sciences Deal Advisory & Strategy Leader

KPMG

Kristin Ciriello Pothier is the KPMG U.S. National Life Sciences Sector Leader, and the Global and National Healthcare and Life Sciences (HCLS) Deal Advisory & Strategy Leader. With almost 30 years in strategy consulting and scientific and clinical research; she focuses on commercial and growth strategy, and M&A for pharmaceutical, diagnostics, device, and consumer health companies, investors, and medical institutions worldwide. She is a leader in precision medicine and diagnostics innovations with hands-on experience developing product and service strategies across the Americas, Europe, Asia, and the Middle East. Her book, *Personalizing Precision Medicine*, has garnered attention worldwide for its all-inclusive and comprehensive look at global precision medicine.

Kristin also works with health systems and affiliated organizations on innovative services strategies, diligences, and operations, including clinical trial program development, laboratory builds, health IT, hospital services, and clinical outreach.

Earlier in her career, Kristin was a partner and the global head of Life Sciences Strategy at EY-Parthenon and a partner at Health Advances, where she built both from single-deal offices into global organizations. She started her career as a geneticist and clinical diagnostics developer at Genome Therapeutics and Genzyme/Sanofi.



Daryl Pritchard, Ph.D.

President

Personalized Medicine Coalition

Daryl Pritchard, Ph.D., is the President at the Personalized Medicine Coalition, responsible for all executive aspects of the organization including operations, member and partner development, communications, strategic planning, and business development as the Coalition drives its mission in education, advocacy and evidence development to advance personalized medicine.

Prior to becoming President of PMC, he served as Senior Vice President, Science Policy, where he led PMC's efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory and payment policies.

He previously held leadership positions at the National Pharmaceutical Council, Biotechnology Innovation Organization, and the American Association for Dental Research. He was awarded the first National Human Genome Research Institute/ American Society of Human Genetics Fellowship in Genetics Policy and served as a Congressional staff member in the U.S. House of Representatives.



Dan Roden, M.D.

Professor of Medicine, Pharmacology & Biomedical Informatics;
Senior Vice President, Personalized Medicine

Vanderbilt University Medical Center

Dan Roden grew up in Montreal and received his medical degree at McGill University before fellowships in Clinical Pharmacology and Cardiology at Vanderbilt, where he joined the faculty. His research examines how genetic variation affects human disease susceptibility, with special interests in pharmacogenetics and genetic determinants of abnormal heart rhythms, especially drug-induced.

After serving as chief of Clinical Pharmacology for 12 years, he began leading Vanderbilt's Personalized Medicine program (2006), building internationally recognized initiatives including the >350K-sample biobank BioVU and the EHR-based preemptive pharmacogenetic program PREDICT. He served as PI for the Vanderbilt Pharmacogenomics Research Network (2001–2021), and now co-PI for the Electronic Medical Records and Genomics (eMERGE) Network (2007–2026), the genomic Learning Healthcare System (2024–2029), and the Data and Research Center for the US NIH *All of Us* program.

Dr. Roden has received numerous awards from the American Society for Clinical Pharmacology and Therapeutics, Heart Rhythm Society, American Heart Association, McGill, and Ohio State University. He has been elected to the American Society for Clinical Investigation, the Association of American Physicians, and fellowship in the American Association for the Advancement of Science.



Anthony (Nino) Sireci, M.D.

Senior Vice President, Clinical Biomarkers, Laboratories & Diagnostics

Eli Lilly

Dr. Sireci is a board-certified Clinical Pathologist and a practicing molecular pathologist. Prior to joining Loxo, he was an Assistant Professor of Pathology and Cell Biology at Columbia University and a medical director in the Laboratory of Personalized Genomic Medicine at Columbia Medical Center. He is an active member of the Association for Molecular Pathology (AMP) where he serves on the organizations' Strategy Committee and was the former vice chair for new codes and pricing on the Economic Affairs Committee. He is also a member of the Pathology Coding Caucus in the College of American Pathologists (CAP) and the Molecular Pathology Advisory Group in the American Medical Association (AMA). Dr. Sireci received a B.A. in chemistry from New York University, an M.D. from the Johns Hopkins University School of Medicine and a Masters in Biostatistics from the Mailman School of Public Health at Columbia University. He completed his residency training in Clinical Pathology in the New York-Presbyterian Hospital/Columbia, where he also served as chief resident.



Lauren Silvis, J.D.

Senior Vice President, External Affairs

Tempus AI, Inc.

Lauren Silvis serves as Senior Vice President of External Affairs at Tempus, overseeing regulatory, public policy, government affairs and strategic communications. She has held a number of senior career public health roles, serving as a Senior Advisor at the Department of Health and Human Services, Chief of Staff of the Food and Drug Administration and Deputy Center Director for Policy in FDA's Center for Devices and Radiological Health. She currently serves as a member of the Council of Councils for the National Institutes of Health and Board Vice Chair for the Personalized Medicine Coalition. During her time in government, she advanced policies to promote innovation in precision medicine, real world evidence, clinical trials and digital health. Earlier in her career, she was a partner at the international law firm Sidley Austin LLP, focusing on regulation of pharmaceuticals and medical devices. Lauren graduated from Duke University and earned her law degree from Georgetown University Law Center.



AmirAli Talasaz, Ph.D.

Co-Chief Executive Officer & Director

Guardant Health

AmirAli Talasaz, Ph.D. is the Co-Chief Executive Officer & Director of Guardant Health and has served as the Co-Chief Executive Officer since August 2021. Prior to founding Guardant, Dr. Talasaz held various positions at Illumina, including Senior Director of Diagnostics Research from October 2011 to June 2012, where he led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. In March 2008, he founded Auriphex Biosciences, Inc., which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. During his academic years, he led the Technology Development group at SGTC. He received his Ph.D. degree in electrical engineering, M.S. degree in electrical engineering and M.S. degree in management science and engineering from Stanford University.



Apostolia Tsimberidou, M.D., Ph.D.

Professor, Department of Investigational Cancer Therapeutics,
Division of Cancer Medicine

The University of Texas MD Anderson Cancer Center

Since joining the faculty at The University of Texas MD Anderson Cancer Center in 2001, Dr. Tsimberidou's clinical research has focused on the development of therapeutic strategies for advanced hematologic malignancies and solid tumors. She has served as the Principal Investigator for 20 investigator-initiated clinical trials for the treatment of patients with advanced cancer.



Alex Vadas, Ph.D.

Managing Director & Partner

L.E.K. Consulting

Alex Vadas, Ph.D. is a Managing Director and Partner in L.E.K. Consulting's Healthcare practice and co-leads the Life Sciences Enablers practice.

He has worked with a broad range of financial and strategic clients from venture-backed to global multi-nationals in the areas of corporate strategy, product strategy and planning, and transaction support.

Alex focuses on major innovation areas in life sciences, including life sciences tools and technologies such as genomics, proteomics, cell analysis, multi-omics, and AI-enabled platforms. His work also spans diagnostics and precision medicine, with emphasis on advanced diagnostics, precision oncology, molecular diagnostics, liquid biopsy, and pathology. In addition, Alex is engaged in advanced therapy bioprocessing and manufacturing, covering monoclonal antibodies as well as cell, gene, and nucleic acid therapies.

He joined L.E.K. in 2000 and received both his Bachelor of Science and Doctorate of Philosophy degrees in chemical engineering from the University of California, Los Angeles.



Ayah Ziyada, Ph.D. Candidate

Precision Medicine Program Manager

*Center for Clinical Precision Medicine and Genomics,
Hamad Medical Corporation, Qatar*

Ayah Ziyada is the Precision Medicine Program Manager at the Center for Clinical Precision Medicine and Genomics, Hamad Medical Corporation (HMC) in Qatar, where she leads initiatives to position HMC as a model for precision medicine. She holds a BPharm from Dubai Medical University and a M.S. in Genomics and Precision Medicine from Hamad Bin Khalifa University, where her research explored innovative imputation strategies for underrepresented, low-coverage whole genomes.

Certified by the American Society of Health-System Pharmacists, Ayah is a member of the PGRN Global Committee, the CPIC Guideline Consortium, and the Consortium for Healthcare AI. Her expertise spans pharmacogenomics, AI-enabled healthcare, and deploying precision medicine innovations into clinical practice.

Ayah helped launch HMC's first precision medicine incubation program, creating pathways for healthcare startups, business ventures, and industry partnerships to accelerate the adoption of validated technologies. She leads enterprise-wide projects that integrate precision medicine into clinical workflows, improve patient outcomes, and foster a culture of innovation.

About Us

The Personalized Medicine Coalition, a 501(c)3 organization comprised of 14 distinct stakeholder groups within health care, promotes the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and health systems.



Thank You to Our Supporters

Gold



Silver



Bronze



Benefactor



Friend





We're working to drive patient-centered progress in innovation, affordability and access to life saving prescription medicines.



Learn more at [PhRMA.org](https://www.phrma.org)



Partner with Precision

Accelerate your Companion Diagnostic development program by leveraging our technical expertise, global infrastructure and decades of proven experience enabling targeted therapeutics for the world's leading pharma companies.



Learn more about our comprehensive CDx Services for Pharma

Contact us at cdxpartnerships@agilent.com



WE'LL NEVER STOP LOOKING FOR ANSWERS
FOR PATIENTS WHO NEED THEM.



FDA
APPROVED

MI CANCER SEEK®

The First and Only Simultaneous Whole Exome- and Whole Transcriptome-Based Assay with CDx Indications for All Solid Tumors in Adult and Pediatric Patients for Therapy Selection

FDA-Approved CDx Indications:

1

Pan-Cancer

5

Tumor-Specific

8

CDx Indications

20

Therapies*



*For the most current information about the device indications for the therapeutic products, go to: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools#Group_Labeling

For important product information, visit Label.MICancerSeek.com.



To learn more, visit CarisLifeSciences.com/MICancerSeek.

©2025 Caris MPI, Inc. All rights reserved.
MAT-TP-000585 03 OCT 2025



For more information about PMC or next year's annual conference,
please visit us at personalizedmedicinecoalition.org.



PERSONALIZED
MEDICINE COALITION

pmc@personalizedmedicinecoalition.org